A Pilot Trial of Pioglitazone HCl and Tretinoin in ALS: Cerebrospinal Fluid Biomarkers to Monitor Drug Efficacy and Predict Rate of Disease Progression

<table>Levels of tau in CSF of patients in active arm versus placebo arm at baseline and after six months of therapy. (*Significant difference in levels of tau at baseline between the two groups, <i>P</i> = 0.02 by Mann-Whitney <i>t</i>-test). Error bars denote standard deviation.</table>

Neurology Research International

fig1

Figure 1

Figure 1: A Pilot Trial of Pioglitazone HCl and Tretinoin in ALS: Cerebrospinal Fluid Biomarkers to Monitor Drug Efficacy and Predict Rate of Disease Progression 

Figure 1 | A Pilot Trial of Pioglitazone HCl and Tretinoin in ALS: Cerebrospinal Fluid Biomarkers to Monitor Drug Efficacy and Predict Rate of Disease Progression 